Journal
CEPHALALGIA
Volume 30, Issue 11, Pages 1346-1353Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0333102410363491
Keywords
migraine; calcitonin gene-related peptide; glyceryl trinitrate; nitric oxide; olcegepant; human headache model
Categories
Funding
- Lundbeck Foundation via the Lundbeck Foundation Center for Neurovascular Signaling (LUCENS)
- Merck
- Pfizer
- Minster Pharmaceuticals
- RoxRo Pharma
- MAP Pharmaceuticals
- NeurAxon
- Lundbeck
Ask authors/readers for more resources
There is a striking similarity between the migraine-provoking effect of the nitric oxide (NO) donor glyceryl trinitrate (GTN) and that of calcitonin gene-related peptide (CGRP). We tested the hypothesis that NO releases CGRP to cause the delayed migraine attack after GTN. Methods: In a double-blind-cross-over study, 13 migraine without aura (MO) patients were administered GTN 0.5 mu g/kg/minute for 20 minutes and subsequently BIBN4096BS (olcegepant) 10 mg or placebo. Headache scores and development of MO were followed for 24 hours. Results: MO developed in seven of 13 with olcegepant and in nine of 13 with placebo (p = 0.68). The headache scores were similar after the two treatments (p = 0.58). Thus CGRP receptor blockade did not prevent GTN-induced migraine. Conclusions: The present study indicates that NO does not induce migraine by liberating CGRP. The most likely explanation for our findings is that CGRP has its effect higher than NO in the cascade of events leading to MO attacks.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available